Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

A study to evaluate how JNJ-77242113 is absorbed by the body in healthy participants for the treatment of inflammatory diseases.

Investigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study aims to investigate how the body absorbs a new drug called JNJ-77242113. The research focuses on inflammatory diseases, which are conditions where the body's immune system causes swelling and irritation in various parts of the body. Specifically, the study looks at different versions of a film-coated tablet, which is a pill covered with a thin layer to make it easier to swallow or to control how it dissolves. The investigation will compare an immediate-release formulation, meaning the medicine is released into the body quickly after being swallowed, with a previous version of the same medicine.

The study involves a crossover design, which means participants will receive different versions of the medication at different times during the trial. This approach allows for a comparison of how the body processes each version. Additionally, the study will evaluate the food effect, which refers to how eating meals might change the way the medicine is absorbed into the bloodstream. All participants will take the medication through oral use, meaning the tablets are swallowed by mouth.

The research process

The trial runs in 2 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Administration of the first medication formulation

    A single dose of 200 mg of JNJ-77242113 in a film-coated tablet form is taken by mouth.

    This dose is administered under fasted conditions, which means no food is consumed for a period before taking the tablet.

  2. Step 2

    Administration of the second medication formulation

    After a designated period, a second single dose of 200 mg of JNJ-77242113 in a film-coated tablet form is taken by mouth.

    This step follows a crossover design, meaning the different versions of the tablet are compared by receiving each one at different times.

Who can join the trial?

7 criteria

  • Both men and women can participate if they are between 18 and 60 years old at the time of the initial screening.
  • Participants must be considered healthy based on a physical exam, a review of their medical history, and their vital signs (such as blood pressure and pulse).
  • Participants must have a normal 12-lead ECG, which is a test that records the electrical activity of the heart to ensure it is working correctly.
  • Participants must have normal results from clinical laboratory tests, which are medical tests performed on blood or other body fluids to check overall health.
  • A person's Body Mass Index (BMI), which is a measure of body fat based on height and weight, must be between 18.0 and 30.0.
  • Participants must weigh at least 50.0 kg (about 110 pounds).
  • Women who can become pregnant are not eligible; they must be postmenopausal (no longer having menstrual periods) or permanently sterile (unable to have children).

Who cannot join the trial?

14 criteria

  • Having a history of or currently suffering from any serious medical condition, such as cardiac arrhythmias (irregular heartbeats) or other heart diseases.
  • Having hematologic disease (disorders that affect the blood) or coagulation disorders (conditions that affect how your blood clots).
  • Having lipid abnormalities (unhealthy levels of fats, such as cholesterol, in your blood).
  • Having significant pulmonary disease (serious lung problems), including bronchospastic respiratory disease (conditions like asthma where the airways narrow and make breathing difficult).
  • Having diabetes mellitus (a condition where blood sugar levels are too high).
  • Having hepatic or renal insufficiency (problems with how the liver or kidneys function).
  • Having thyroid disease (conditions related to the thyroid gland that controls your body's metabolism).
  • Having neurologic or psychiatric disease (conditions affecting the brain, nerves, or mental health).
  • Having an active infection (an illness caused by germs like bacteria or viruses).
  • Any other illness that the study doctor believes might prevent you from joining or might make the study results difficult to understand.
  • A history of malignancy (cancer) before the screening process began.
  • Known allergies, hypersensitivity (an exaggerated immune response), or intolerance to the study medicine or its excipients (the inactive ingredients used to make the pill).
  • A history of gastrointestinal disease (problems with the stomach or digestive tract).
  • A history of surgical resection (the medical removal of an organ or part of the body through surgery).
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

JNJ-77242113 is an experimental medication being tested in this study to see how well the body absorbs it when taken as a tablet. The study compares different versions of this tablet to understand how quickly it enters the bloodstream and how food might affect its absorption.

What is already known about the treatment

JNJ-77242113-AAC - This medication is taken by mouth in the form of a film-coated tablet. Currently being studied in clinical trials, it is being investigated for its potential to treat various inflammatory conditions related to the immune system. It works by targeting specific molecules in the body to help reduce excessive immune responses. This substance is classified as an investigational drug used to manage immune system diseases.

Investigated diseases

Inflammatory conditions - These are states where the body's immune system reacts to perceived threats, causing swelling and redness in tissues. The process typically begins when the immune system sends specialized cells to a specific area to fight off potential harm. This response can cause local heat, pain, and physical changes in the affected part of the body. Over time, the immune response may become persistent or spread to different areas. The intensity and duration of these conditions can vary depending on the underlying cause.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-504720-26-00Estimated enrolment24 patientsSponsorJanssen Cilag International

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).